首页|期刊导航|Oncology Research|Impact of Germline BRCA1/2 Mutations on Clinical Outcomes in Metastatic Triple-Negative Breast Cancer Patients Treated with Sacituzumab Govitecan—An International CEBCC Study from Poland,the Czech Republic and Slovakia

Impact of Germline BRCA1/2 Mutations on Clinical Outcomes in Metastatic Triple-Negative Breast Cancer Patients Treated with Sacituzumab Govitecan—An International CEBCC Study from Poland,the Czech Republic and SlovakiaOA

中文摘要

Background:Germline breast cancer susceptibility gene 1/2(BRCA1/2)variants guide breast cancer treatment,but their clinical relevance in metastatic triple-negative breast cancer(mTNBC)treated with sacituzumab govitecan(SG)remains unclear.The study aimed to evaluate the association between BRCA status and outcomes in SG-treated mTNBC.Methods:We retrospectively analyzed 264 patients with mTNBC and known germline BRCA1/2(gBRCA1/2)status who received SG between August 2021 and May 2025 across multiple oncology centers in Poland,the Czech Republic and Slovakia.Survival outcomes were compared between patients with gBRCA1/2 mutations(gBRCA1/2m)and those with gBRCA1/2 wild-type(gBRCA1/2wt)using Kaplan–Meier estimates,the log-rank test,and multivariable Cox proportional hazards models.Two-sided p<0.05 was considered statistically significant.Results:Among 264 patients,35(13.3%)were gBRCA1/2m and 229(86.7%)were gBRCA1/2wt.After a median follow-up of 9.9 months,the median progression-free survival(PFS)was 4.5 months(95%confidence interval[CI]2.1–6.3)in gBRCA1/2 carriers versus 4.2 months(95%CI 3.5–5.8)in gBRCA1/2wt patients(p=0.10).Median overall survival(OS)was 9.1 months(95%CI 5.0–15.1)in gBRCA1/2 carriers compared to 11.5 months(95%CI 10.3–13.5)in gBRCA1/2wt patients(p=0.26).Brain metastases were more frequent in carriers(20%vs.8.3%,p=0.06).In multivariable analysis,Eastern Cooperative Oncology Group(ECOG)performance status was the only independent predictor of poorer survival(hazard ratio 1.97,95%CI 1.42–2.74,p<0.01),while gBRCA1/2 status showed no independent association.Conclusions:In this large retrospective cohort of mTNBC patients treated with SG,the presence of gBRCA1/2 was not associated with statistically significant differences in PFS or OS.

Renata Pacholczak-Madej;Mirosława Püsküllüoğlu;Anna Polakiewicz-Gilowska;Małgorzata Pieniążek;Iveta Kolářová;Miroslava Malejčíková;Lenka Rušinová;MilošHolánek;Renata Soumarová;Karolina Winsko-Szczęsnowicz;JustynaŻubrowska;Aleksandra Konieczna;Agnieszka Młodzińska;Daniel Krejčí;Iwona Danielewicz;Magdalena Szymanik-Resko;Tomasz Ciszewski;Maja Lisik-Habib;Anika Pękala;HanaŠtudentová;JanŠustr;Bogumiła Czartoryska-Arłukowicz;AleksandraŁacko;Jolanta Smok-Kalwat;MichałJarząb;Zuzana Bielčiková;Marcin Kubeczko

Department of Gynecological Oncology,Maria Sklodowska-Curie National Research Institute of Oncology,Kraków Branch,Kraków,Poland Department of Anatomy,Jagiellonian University Medical College,Krakow,PolandDepartment of Clinical Oncology,Maria Sklodowska-Curie National Research Institute of Oncology,Kraków Branch,Kraków,PolandBreast Cancer Center,Maria Sklodowska-Curie National Research Institute of Oncology,Gliwice,PolandLower Silesian Comprehensive Cancer Center,Wrocław Medical University,Wrocław,PolandDepartment of Oncology and Radiotherapy,Faculty of Medicine in Hradec Královéand University Hospital in Hradec Králové,Charles University,Hradec Králové,Czech RepublicOncology Clinic of LFUK,National Cancer Institute,Bratislava,SlovakiaDepartment of Oncology,Stefan Kukura Hospital Michalovce,Michalovce,SlovakiaDepartment of Comprehensive Cancer Care,Faculty of Medicine,Masaryk University,and Masaryk Memorial Cancer Institute,Brno,Czech RepublicDepartment of Oncology,Third Faculty of Medicine,Charles University,University Hospital KralovskéVinohrady,Prague,Czech RepublicDepartment of Clinical Oncology,Maria Sklodowska-Curie Bialystok Oncology Center,Białystok,PolandDepartment of Clinical Oncology,Holy Cross Cancer Center,Kielce,PolandDepartment of Breast Cancer and Reconstructive Surgery,Maria Sklodowska-Curie National Research Institute of Oncology,Warsaw,PolandDepartment of Breast Cancer and Reconstructive Surgery,Maria Sklodowska-Curie National Research Institute of Oncology,Warsaw,PolandDepartment of Oncology,First Faculty of Medicine,Charles University in Prague,and Bulovka University Hospital,Prague,Czech RepublicDepartment of Oncology and Radiotherapy,Szpitale Pomorskie sp.z o.o.,Gdynia,PolandDepartment of Oncology and Radiotherapy,Szpitale Pomorskie sp.z o.o.,Gdynia,PolandDepartment of Metabolic Diseases and Immuno-Oncology,Medical University of Lublin,Lublin,PolandDepartment of Proliferative Diseases,Nicolaus Copernicus Multidisciplinary Centre for Oncology and Traumatology,Lodz,PolandDepartment of Proliferative Diseases,Nicolaus Copernicus Multidisciplinary Centre for Oncology and Traumatology,Lodz,PolandDepartment of Oncology,Faculty of Medicine and Dentistry,Palacky University and University Hospital,Olomouc,Czech RepublicDepartment of Oncology and Radiotherapy,Faculty of Medicine in Pilsen,Charles University,and University Hospital Pilsen,Plzen,Czech RepublicDepartment of Clinical Oncology,Maria Sklodowska-Curie Bialystok Oncology Center,Białystok,PolandLower Silesian Comprehensive Cancer Center,Wrocław Medical University,Wrocław,PolandDepartment of Clinical Oncology,Holy Cross Cancer Center,Kielce,PolandBreast Cancer Center,Maria Sklodowska-Curie National Research Institute of Oncology,Gliwice,PolandDepartment of Oncology,First Faculty of Medicine,Charles University,and General University Hospital,Prague,Czech RepublicBreast Cancer Center,Maria Sklodowska-Curie National Research Institute of Oncology,Gliwice,Poland

医药卫生

Triple-negative breast cancersacituzumab govitecanBRCA1/2 germline mutationsreal-world evidenceinternational multicenter cohort

《Oncology Research》 2026 (6)

P.457-470,14

10.32604/or.2026.076384

评论